Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma

Human Gene Therapy
L C BowmanMalcolm Brenner

Abstract

Tumor cells that have been genetically modified to express immunostimulatory genes will induce effective antitumor responses in a range of syngeneic animal models. For human applications, transduced autologous tumor cell lines are often difficult or impossible to prepare, so that there are strong incentives for substituting a standardized allogeneic tumor cell line. However, such lines may be inferior immunogens if they differ from host tumors in the antigens they express. We have evaluated the safety, immunostimulatory, and antitumor activity of an interleukin-2-secreting allogeneic neuroblastoma cell line in 12 children with relapsed stage IV neuroblastoma. They received two to four subcutaneous injections of cells in a dose-escalating schedule, up to a maximum of 10(8) cells per injection. There was induration and pruritus at the injection site, and skin biopsies revealed mild panniculitis with CD3+ cells surrounding scanty residual tumor cells. There was a limited but significant peripheral monocytosis. No patient showed any increase in direct cytotoxic effector function against the immunizing cell line, but 3 patients had a rise in the frequency of neuroblastoma-reactive cytotoxic T lymphocyte precursor cells. One child ha...Continue Reading

References

Jan 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J G PoleJ Shuster
Jan 21, 1991·International Journal of Cancer. Journal International Du Cancer·S J RussellM K Collins
Apr 1, 1991·Pediatric Clinics of North America·N K Cheung
May 1, 1991·The Journal of Experimental Medicine·T BlankensteinT Diamantstein
Jun 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R Anderson, P F Coccia
Apr 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A T LookG M Brodeur
Feb 1, 1989·Archives of Surgery·J V ReynoldsJ M Daly
Jan 1, 1982·British Journal of Cancer·J PritchardJ Graham-Pole
Jul 1, 1995·The Journal of Experimental Medicine·X J Zhao, N K Cheung
Jul 14, 1995·Cell·N K Nanda, E E Sercarz
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B Gansbacher
Jul 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P MathewW Crist
Feb 1, 1994·Human Gene Therapy·R I Tepper, J J Mulé
Dec 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·G J NabelA E Chang
Jan 1, 1996·Advances in Immunology·R A Henderson, O J Finn
Dec 24, 1996·Proceedings of the National Academy of Sciences of the United States of America·G J NabelA E Chang

❮ Previous
Next ❯

Citations

Oct 23, 2001·International Journal of Cancer. Journal International Du Cancer·C RossigM K Brenner
Nov 28, 2007·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Michael R Verneris, John E Wagner
Dec 21, 2000·Current Oncology Reports·C L Mackall, L J Helman
Sep 28, 2000·Current Opinion in Immunology·N Mach, G Dranoff
Feb 22, 2002·Critical Reviews in Oncology/hematology·S Burdach, H Jürgens
Feb 1, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Anthony T Power, John C Bell
Apr 12, 2001·Journal of Internal Medicine·M K Brenner
Oct 4, 2005·The Cancer Journal·Raphaël F Rousseau, Malcolm K Brenner
Sep 29, 2011·The Cancer Journal·Giorgio ParmianiVincenzo Russo
Aug 15, 1998·Vox Sanguinis·M K BrennerC M Rooney
Jul 15, 2011·Immunotherapy·Vito PistoiaLizzia Raffaghello
Sep 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·C Hirschmann-JaxM K Brenner
Nov 15, 2008·Cancer Immunology, Immunotherapy : CII·J F M JacobsP M Hoogerbrugge
Aug 26, 2014·Future Oncology·Christian M CapitiniPaul M Sondel
Oct 6, 2011·Seminars in Cancer Biology·Robert C Seeger
Mar 2, 2012·Pediatric Blood & Cancer·Peter E ZageSusan L Cohn
Jul 11, 2009·Pediatric Blood & Cancer·Juliet C Gray, Janice A Kohler
Jul 2, 2005·Journal of Pediatric Surgery·Sean J BarnettDaniel A Saltzman
Feb 13, 2003·Pediatric Clinics of North America·Carla B Golden, James H Feusner
Aug 2, 2014·Cytotherapy·Meenakshi HegdeNabil Ahmed
Mar 24, 2000·Clinical Immunology : the Official Journal of the Clinical Immunology Society·D M Pardoll
Oct 14, 2005·Expert Review of Anticancer Therapy·Gregory A Hale
May 23, 2001·Leukemia·V F Van TendelooZ N Berneman
Mar 10, 2005·International Journal of Cancer. Journal International Du Cancer·Lilian StärckPeter T Daniel
Apr 21, 2006·Expert Review of Neurotherapeutics·Lizzia Raffaghello, Vito Pistoia
Jun 23, 2011·Expert Review of Vaccines·Byram W Bridle
Sep 25, 2019·Cancers·Sévérine de BruijnEva Lion
Jan 25, 2003·Ophthalmic Plastic and Reconstructive Surgery·Matthew W WilsonLaura C Bowman
Sep 13, 2020·Cells·Simone HagerMatthias Bros
Mar 24, 2004·Paediatric Drugs·Robert E Goldsby, Katherine K Matthay
Dec 21, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Judith WienkeJan J Molenaar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.